• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medications are not effective. A customized treatment may be the answer.

Cue is an intervention platform that converts sensors that are passively gathered from smartphones into customized micro-interventions for improving mental health. We analysed the best way to treat depression-fit personalized ML models for each subject using Shapley values to understand their feature predictors and uncover distinct features that deterministically change mood over time.

Predictors of Mood

Depression is the leading cause of mental illness across the world.1 Yet only half of those affected receive treatment. To improve the outcomes, healthcare professionals must be able to identify and treat patients with the highest chance of responding to certain treatments.

The treatment of depression can be personalized to help. Utilizing mobile phone sensors as well as an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from the treatments they receive. With two grants awarded totaling more than $10 million, they will use these tools to identify biological and behavioral predictors of response to antidepressant medications and psychotherapy.

So far, the majority of research into predictors of depression treatment effectiveness has centered on the sociodemographic and clinical aspects. These include demographic factors such as age, sex and education, clinical characteristics including the severity of symptoms and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these variables can be predicted by the data in medical records, very few studies have utilized longitudinal data to study predictors of mood in individuals. Few also take into account the fact that mood can vary significantly between individuals. Therefore, it is important to develop methods which allow for the identification and quantification of individual differences in mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to detect patterns of behaviour and emotions that are unique to each individual.

In addition to these modalities, the team developed a machine-learning algorithm to model the changing predictors of each person's depressed mood. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype has been associated with CAT DI scores that are a psychometrically validated symptoms severity scale. The correlation was low, however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is the leading cause of disability in the world1, but it is often misdiagnosed and untreated2. In addition an absence of effective interventions and stigmatization associated with depressive disorders prevent many people from seeking help.

To help with personalized treatment, it is essential to identify predictors of symptoms. However, current prediction methods are based on the clinical interview, which is not reliable and only detects a small number of features that are associated with depression.2

Machine learning can increase the accuracy of the diagnosis and tms treatment for depression (Click At this website) of depression by combining continuous digital behavior phenotypes collected from smartphone sensors with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements and capture a wide range of distinctive behaviors and activity patterns that are difficult to record with interviews.

The study included University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and alcohol depression treatment (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical treatment according to the severity of their depression. Participants with a CAT-DI score of 35 65 were assigned online support with a coach and those with scores of 75 were sent to in-person clinical care for psychotherapy.

Participants were asked a series of questions at the beginning of the study about their demographics and psychosocial characteristics. The questions asked included education, age, sex and gender and financial status, marital status, whether they were divorced or not, their current suicidal thoughts, intent or attempts, and how often they drank. The CAT-DI was used to assess the severity of post stroke depression treatment symptoms on a scale from zero to 100. CAT-DI assessments were conducted every other week for the participants that received online support, and every week for those who received in-person care.

Predictors of Treatment Response

Personalized depression treatment is currently a major research area and many studies aim at identifying predictors that will enable clinicians to determine the most effective medications for each individual. Particularly, pharmacogenetics is able to identify genetic variations that affect the way that the body processes antidepressants. This lets doctors select the medication that are most likely to work for each patient, while minimizing the amount of time and effort required for trials and errors, while eliminating any adverse consequences.

Another promising method is to construct models for prediction using multiple data sources, combining clinical information and neural imaging data. These models can be used to determine the variables that are most likely to predict a specific outcome, such as whether a medication can improve symptoms or mood. These models can be used to determine the patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of the current therapy.

A new generation of studies utilizes machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and increase predictive accuracy. These models have been shown to be useful in predicting the outcome of treatment, such as response to antidepressants. These approaches are becoming more popular in psychiatry and will likely become the norm in the future clinical practice.

The study of depression's underlying mechanisms continues, in addition to ML-based predictive models. Recent research suggests that depression is connected to the malfunctions of certain neural networks. This theory suggests that individual depression treatment will be built around targeted therapies that target these neural circuits to restore normal functioning.

One method of doing this is through internet-delivered interventions that offer a more individualized and personalized experience for patients. A study showed that an internet-based program helped improve symptoms and improved quality of life for MDD patients. Additionally, a randomized controlled trial of a personalized approach to depression treatment showed an improvement in symptoms and fewer side effects in a significant percentage of participants.

Predictors of adverse effects

In the treatment of depression, one of the most difficult aspects is predicting and determining the antidepressant that will cause no or minimal negative side negative effects. Many patients are prescribed a variety of medications before settling on a treatment that is effective and tolerated. Pharmacogenetics provides an exciting new avenue for a more effective and precise approach to selecting antidepressant treatments.

There are a variety of variables that can be used to determine the antidepressant to be prescribed, including genetic variations, phenotypes of patients like gender or ethnicity and co-morbidities. However, identifying the most reliable and reliable predictive factors for a specific treatment will probably require controlled, randomized trials with considerably larger samples than those typically enrolled in clinical trials. This is due to the fact that it can be more difficult to determine interactions or moderators in trials that comprise only one episode per person instead of multiple episodes spread over a long period of time.

Furthermore, predicting a patient's response will likely require information about the comorbidities, symptoms profiles and the patient's own perception of the effectiveness and tolerability. Presently, only a handful of easily assessable sociodemographic and clinical variables appear to be reliable in predicting the severity of MDD like gender, age race/ethnicity, BMI, the presence of alexithymia and the severity of depressive symptoms.

The application of pharmacogenetics to depression treatment is still in its infancy and there are many hurdles to overcome. First is a thorough understanding of the genetic mechanisms is required, as is a clear definition of what constitutes a reliable predictor for treatment response. In addition, ethical concerns such as privacy and the responsible use of personal genetic information should be considered with care. In the long term, pharmacogenetics may provide an opportunity to reduce the stigma that surrounds mental health treatment and to improve the treatment outcomes for patients with depression. As with any psychiatric approach, it is important to take your time and carefully implement the plan. At present, the most effective option is to offer patients a variety of effective medications for depression and encourage them to speak openly with their doctors about their experiences and concerns.